After receiving U.S. Food and Drug Administration approval in October 2008, Pfizer launched its overactive bladder (OAB) treatment Toviaz™ in a carded blister housed in a paperboard outer sleeve and bundled with regulatory literature for presentation to consumers by prescribing physicians.
Last year, Pfizer worked with AmerisourceBergen company Anderson Packaging to transition to Anderson’s proprietary IntuiDose™ child-resistant compliance-prompting format for the physician’s sample package. The four-panel wallet pack contains 14 8-mg doses. The user pushes each pill out of each blister cavity from a three-ply cold-formed base film. The lidding is a 15#, paper-supported, push-through 0.008 foil. The pack uses a 16-pt board stock, coated on two sides (C2S), with a heat-seal coating applied on press during printing to help reduce overall cost and material use. Also, there are 4-mg and 8-mg strength versions, distinguished by an orange or green color scheme.
